(Reuters) – The U.S. National Institutes of Health (NIH) said on Tuesday they stopped a trial of convalescent blood plasma in treating patients with mild to moderate COVID-19 symptoms as it is unlikely to benefit. to this group.
The NIH said its decision was based on the findings of an independent data monitoring board. (bit.ly/3rbOIdh)
The health agency’s move comes less than two months after an international convalescent plasma test was stopped because no benefit was found. Other studies carried out in India and Argentina have also found no apparent benefit for those seriously ill with the disease.
The US trial had enrolled 511 of 900 participants, who were given blood plasma from recovered COVID-19 patients or a placebo.
A recent analysis indicated that there was no significant difference in the proportion of patients who needed emergency treatment, had to be hospitalized, or died within 15 days of entering the trial, the NIH said.
Report of Manas Mishra in Bengaluru; Edited by Shailesh Kuber